Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Advances in the systemic treatment of metastatic melanoma.

Oncology (Williston Park, N.Y.) - 1 May 2013

Yushak Melinda, Kluger Harriet M, Sznol Mario

Abstract excerpt

Prior to 2011, the only commercially available agents commonly used to treat metastatic melanoma-including dacarbazine, temozolomide (Temodar), fotemustine, carboplatin, paclitaxel, and interleukin-2-demonstrated limited efficacy, and no study involving these agents had shown an improvement in overall survival. The standard of care for the treatment of metastatic melanoma was radically changed by the subsequent...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Immunologic Factors
Share to Immunotherapy, Adoptive
Share to Ipilimumab

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Nivolumab

Share to Oximes

Share to Pyridones

Share to Pyrimidinones

Share to Vemurafenib

Source

Open in PubMed Open full text

Identifiers

PMID: 25184258
PMCID: PMC6092183

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Advances in the systemic treatment of metastatic melanoma.PMID 25184258Read ↗

Metastatic melanoma treatment: Combining old and new therapies.Semantic proximity Read ↗

First line treatment of BRAF mutated advanced melanoma: Does one size fit all?Semantic proximity Read ↗

New drug targets in metastatic melanoma.Semantic proximity Read ↗

Recent Progress in Mutation-driven Therapy, Immunotherapy and Combination Therapy for the Treatment of Melanoma.Semantic proximity Read ↗

Molecularly targeted therapies for melanoma.Semantic proximity Read ↗

Frontline approach to metastatic BRAF-mutant melanoma diagnosis, molecular evaluation, and treatment choice.Semantic proximity Read ↗

Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma.Semantic proximity Read ↗

Therapy of metastatic malignant melanoma: on the way to individualized disease control.Semantic proximity Read ↗

Novel therapies in melanoma.Semantic proximity Read ↗

Emerging targeted therapies for melanoma.Semantic proximity Read ↗

Update on the targeted therapy of melanoma.Semantic proximity Read ↗

Immunotherapy or molecularly targeted therapy: what is the best initial treatment for stage IV BRAF-mutant melanoma?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.